4 Healthcare Stock Stories for Thursday Investment Wellness

Acura Pharmaceuticals (NASDAQ:ACUR): Current price $2.64

The FDA has approved updated labeling for Purdue Pharma’s reformulated OxyContin (oxycodone hydrochloride controlled-release) tablets. The new labeling indicates that the product has physical and chemical properties which are expected to make abuse by way of injection difficult and to reduce abuse via the intranasal route (snorting). What is more, because original OxyContin gives the same therapeutic benefits as reformulated OxyContin, but allows for an increased potential for certain types of abuse, the FDA decided that the benefits of original OxyContin no longer surpass its risks, and that original OxyContin was withdrawn from sale for reasons of safety or effectiveness. Thus, the agency will neither accept nor approve any abbreviated new drug applications (generics) that depend upon the approval of original OxyContin.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACUR

Neuralstem (AMEX:CUR): Current price $1.11

The firm announces approval from the FDA to initiate a Phase II trial employing NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). This Phase II dose escalation and safety trial will build out to two centers, Emory University Hospital in Atlanta, where Phase I was recently finished, andALS Clinic at the University of Michigan Health System, in Ann Arbor, subject to approval by the Institutional Review Board at each location. The trial was created to treat as many as 15 patients, in five different dosing cohorts. All of the patients will be ambulatory and reside within close proximity to the research center at which they will participate. The first dozen patients will receive injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function, while the final three patients will receive both cervical and lumbar injections.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CUR

Aeterna Zentaris (NASDAQ: AEZS): Current price $1.79

The company said that its German subsidiary reached binding agreements with various partners and licensees connected to the manufacturing rights and obligations for its Cetrotide product. The main effect of the agreements is to transfer manufacturing rights and to award a manufacturing license for Cetrotide to a subsidiary of Merck KGaA of Darmstadt, in all jurisdictions. The transaction is expected to be completed on or about October 1st, at which time Aeterna Zentaris would receive a one-time payment of about $3.2 million along with certain other payments.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AEZS

Galectin Therapeutics (NASDAQ:GALT): Current price $3.91

On Wednesday, the firm announced that its abstract was accepted by the European Association for the Study of the Liver for presentation on April 27 at the International Liver Congress to be held in Amsterdam. The abstract, Regression of Fibrosis and Reversal of Cirrhosis in Thioacetamide-induced Liver Fibrosis Following Treatment With Galectin Inhibitors shows evidence in a pre-clinical model that Galectin’s drugs can reverse established fibrosis and cirrhosis.The company is a developer of therapeutics that target galectin proteins to treat fibrosis and cancer.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GALT

Investing Insights: Is Clorox Still a Safe Investment?